The Comparison Between Matched Related Donor and Alternative Donor for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acquired Aplastic Anemia: KSBMT2007-02 Study

Backgound; Although allogeneic hematopoietic stem cell transplantation (alloSCT) from matched related donor (MRD) is a standard therapy for severe acquired aplastic anemia (AA), alternative donor (AD) alloSCT is increasing and the survival of alloSCT from AD improves nowadays. Aims: We planned this...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2008-11, Vol.112 (11), p.2997-2997
Main Authors: Kim, Hawk, Koo, Hong Hoe, Kook, Hoon, Kim, Byung Soo, Kim, Sung Hyun, Kim, Hack-Ki, Kim, Hyeoung Joon, Bae, Sung Hwa, Sohn, Sang Kyun, Shin, Ho-Jin, Ahn, Hyo Seop, Won, Jong-Ho, Yoon, Sung-Soo, Lee, Young-Ho, Jeong, Dae-Chul, Jo, Deog-Yeon, Joo, Young-Don, Kim, Min Kyoung, Hyun, Myung Soo, Lee, Kyoo Hyung
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Backgound; Although allogeneic hematopoietic stem cell transplantation (alloSCT) from matched related donor (MRD) is a standard therapy for severe acquired aplastic anemia (AA), alternative donor (AD) alloSCT is increasing and the survival of alloSCT from AD improves nowadays. Aims: We planned this study to review the recent result of alloSCT survival and to compare AD with MRD. Methods: A retrospective study comparing MRD and AD for alloSCT in patients with AA was conducted by Korean Society of Blood and Marrow Transplantation (KSBMT2007-02 study). Results: The patient population was AA, pure red cell aplasia, paroxysmal nocturnal hemoglobinuria, and they underwent alloHSCT from 1997 and 2007. Total 336 patients were enrolled in 24 Korean alloSCT centers. Survival analysis was done in 331 patients because data were not available in 5 patients. Two hundred five adult patients with AA were also analyzed to define the characteristics of adult AA patients. AA was 97.3% and median age at alloSCT was 20.4 (1–62) years old. Median time from diagnosis to alloSCT was 6.2 (0.2–248.4) months. Male was 48.9%. Seventy nine percent patients received bone marrow (BM) as a stem cell source. AD had longer time from diagnosis to alloSCT (p=0.049) and received more peripheral blood (PB) or cord blood (CB) as a stem cell source (16.3% vs. 31.7%, p=0.004). Univeriate analysis showed MSD (p
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V112.11.2997.2997